Disclosed herein is a different and novel approach to cancer vaccines using a subject's own dendritic cells (DCs) and macrophages (Mphs) in combination to present cancer antigens to the immune system. Further disclosed are methods of producing monocyte-derived autologous DCs and Mphs loaded ex vivo with particular whole irradiated cancer cells which generates optimally activated immunostimulatory antigen-presenting cells (APCs) as a superior method for stimulating robust and long-lasting immunity to a particular cancer in vivo as compared with more traditional vaccination methods. Compositions, methods of use and methods for preparation of these DCs and Mphs with cancer cells are also disclosed herein.

The present specification provides libraries of HLA homozygous induced pluripotent cell lines.

It was found that culturing of fibroblasts in the presence of effective amounts of Tumor Necrosis Factor-alpha (TNF-α) known as a factor that induces hemorrhagic necrosis of tumor and Interleukin-4 (IL-4) known for its role in onset of allergic reactions leads to increase in the number of CD106-positive and G-CSF-positive fibroblasts.

A tumor immunotherapy composition based on modified cells, in particular antigen-presenting cells activated by means of attenuated Listeria monocytogenes, a preparation method therefor and an application thereof. Attenuated Listeria monocytogenes carrying a specific antigen plasmid is used to activate antigen-presenting cells, thereby activating WIC antigen presenting properties and a series of cellular immune responses in vivo so as to achieve the purpose of anti-tumor therapy. The described technical solution may specifically activate macrophages and/or dendritic cells, thereby eliciting a series of specific anti-tumor immune responses. The operation process does not require genetic modification of autologous cells, is not limited by tumor type, and operations of the overall process are simple, easy-to-implement and reproducible. The tumor immunotherapy composition of the present disclosure may activate a series of anti-tumor immune responses in vivo, thereby greatly shortening the treatment process and significantly improving targeting ability and safety.

A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3−/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3−/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.

Provided is a method for producing an economical bovine serum composition containing many factors useful for cell proliferation. The method includes a step of performing an anticoagulation treatment of bovine whole blood with an anticoagulant, a step of obtaining a buffy coat and a fraction with a heavier specific gravity than that of the buffy coat from the anticoagulated whole blood, and a step of promoting and activating an interaction between the obtained leukocytes and platelets at a given temperature for not less than a given time to cause secretion or release of a humoral factor from the leukocytes and/or platelets and performing a recoagulation treatment of blood components including the humoral factor with a re-coagulating agent.

The disclosure provides methods for the long-term expansion of granulocyte-macrophage progenitors, the granulocyte-macrophage progenitors generated therefrom, and uses of the granulocyte-macrophage progenitors thereof.

Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.

Disclosed are means, methods and compositions of matter useful for generation of conditioned media from mesenchymal stem cells (MSC). In one embodiment MSC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the MSC lineage. The differentiated MSC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment MSC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.